Cura Therapeutics
 

Developing
Innovative
Immunotherapies
to Cure Cancer

 
 
CART_CELL_INTRO_IMAGE_1.jpg
 

Technology

Cura therapeutics is developing innovative immunotherapies to cure a wide range of cancers, specifically solid malignancies.

Our technologies harness cytokines and cytokine receptors to create multi-functional proteins with potent anti-cancer properties. Our proprietary technology FIST a chimeric protein that simultaneously combines a lymphocyte-stimulatory property of IL-2 while blocking the suppressive effects of tumor-derived transforming growth factor beta (TGFb).

Our chimeric proteins can be used alone or in combination with a wide range of other target therapies or cell-based therapies such as immune checkpoint inhibitors or CART therapies.

FIST Fusion Protein

FIST Fusion Protein


 

Partnering &
Collaborations

Cura Therapeutics is actively seeking strategic partnering opportunities, and collaborations with pharmaceutical and biotechnology companies to develop and commercialize cancer immunotherapies based on our multifunctional fusion proteins.

shutterstock_530971462-667.png